share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Feb 20 20:03
Summary by Futu AI
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on February 20, 2024, the publication of new data in the International Journal of Molecular Sciences demonstrating that its investigational drug opaganib significantly improves long-term survival in a mouse model of lung damage following ionizing radiation exposure. The study indicates opaganib's potential as a medical countermeasure against radiation-induced lung inflammation and fibrosis. Opaganib, a selective sphingosine kinase-2 (SPHK2) inhibitor, is being developed for multiple indications, including Acute Radiation Syndrome (ARS), COVID-19, and oncology. The U.S. National Institutes of Health's Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for its Product Development Program. The drug, which is easy to administer and has a five-year shelf-life, could be stockpiled by governments for use in radiological or nuclear incidents, pending FDA approval. The publication also highlights opaganib's potential benefits in cancer radiotherapy and its host-directed mechanism, which may maintain efficacy against emerging viral variants.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on February 20, 2024, the publication of new data in the International Journal of Molecular Sciences demonstrating that its investigational drug opaganib significantly improves long-term survival in a mouse model of lung damage following ionizing radiation exposure. The study indicates opaganib's potential as a medical countermeasure against radiation-induced lung inflammation and fibrosis. Opaganib, a selective sphingosine kinase-2 (SPHK2) inhibitor, is being developed for multiple indications, including Acute Radiation Syndrome (ARS), COVID-19, and oncology. The U.S. National Institutes of Health's Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for its Product Development Program. The drug, which is easy to administer and has a five-year shelf-life, could be stockpiled by governments for use in radiological or nuclear incidents, pending FDA approval. The publication also highlights opaganib's potential benefits in cancer radiotherapy and its host-directed mechanism, which may maintain efficacy against emerging viral variants.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.